Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma

International Journal of Cancer

Volumn 136, Issue 2, 2015, Pages 289-298

  Chiba, Tetsuhiro ^a   Saito, Tomoko ^a   Yuki, Kaori ^a   Zen, Yoh ^b   Koide, Shuhei ^a   Kanogawa, Naoya ^a   Motoyama, Tenyu ^a   Ogasawara, Sadahisa ^a   Suzuki, Eiichiro ^a   Ooka, Yoshihiko ^a   Tawada, Akinobu ^a   Otsuka, Masayuki ^a   Miyazaki, Masaru ^a   Iwama, Atsushi ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

chaetocin; ESET; H3K9me3; hepatocellular carcinoma; SUV39H1

Indexed keywords

CHAETOCIN; HISTONE LYSINE METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE INHIBITOR; PROTEIN ESET; PROTEIN SUV39H1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; HISTONE; MESSENGER RNA; METHYLTRANSFERASE; REPRESSOR PROTEIN; SMALL INTERFERING RNA; SUV39H1 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; ENZYME INHIBITION; EPIGENETICS; ESET GENE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER CELL LINE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SUV39H1 GENE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DNA METHYLATION; DRUG SCREENING; ENZYME IMMUNOASSAY; ENZYMOLOGY; FOLLOW UP; GENETIC EPIGENESIS; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL CULTURE; TUMOR RECURRENCE; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; FOLLOW-UP STUDIES; HISTONES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; METHYLTRANSFERASES; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922273765     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28985     Document Type: Article

References (34)

1. Dawson MA, Kouzarides T,. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150: 12-27.
2. Esteller M,. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-59.
3. Chi P, Allis CD, Wang GG,. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010; 10: 457-69.
4. Bannister AJ, Kouzarides T,. Regulation of chromatin by histone modifications. Cell Res 2011; 21: 381-95.
5. Sparmann A, van Lohuizen M,. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6: 846-56.
6. Valk-Lingbeek ME, Bruggeman SWM, van Lohuizen M,. Stem cells and cancer: the polycomb connection. Cell 2004; 118: 409-18.
7. Yonemitsu Y, Imazeki F, Chiba T, et al., Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol 2009; 40: 1304-11.
8. Chiba T, Suzuki E, Negishi M, et al., 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012; 130: 2557-67.
9. Nakayama J, Rice JC, Strahl BD, et al., Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 2001; 292: 110-3.
10. Park YS, Jin MY, Kim YJ, et al., The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008; 15: 1968-76.
11. Yokoyama Y, Hieda M, Nishioka Y, et al., Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo. Cancer Sci 2013; 104: 889-95.
12. Rea S, Eisenhaber F, O'Carroll D, et al., Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000; 406: 593-9.
13. Peters AH, O'Carroll D, Scherthan H, et al., Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001; 107: 323-37.
14. Schultz DC, Ayyanathan K, Negorev D, et al., SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev 2002; 16: 919-32.
15. Ceol CJ, Houvras Y, Jane-Valbuena J, et al., The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011: 471: 513-7.
16. Iwama A, Oguro H, Negishi M, et al., Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 2004; 21: 843-51.
17. Dodge JE, Kang YK, Beppu H, et al., Histone H3-K9 methyltransferase ESET is essential for early development. Mol Cell Biol 2004; 24: 2478-86.
18. Fritsch L, Robin P, Mathieu JR, et al., A subset of the histone H3 lysine 9 methyltransferases Suv39h1, G9a, GLP, and SETDB1 participate in a multimeric complex. Mol Cell 2010; 37: 46-56.
19. Zeng J, Ge Z, Wang L, et al., The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology 2010; 138: 981-92.
20. Dalgliesh GL, Furge K, Greenman C, et al., Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-3.
21. Fan DN, Tsang FH, Tam AH, et al., Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology 2013; 57: 637-47.
22. Pogribny IP, Ross SA, Tryndyak VP, et al., Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 2006; 27: 1180-6.
23. Chappell G, Kutanzi K, Uehara T, et al., Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. Int J Cancer 2014; 134: 2778-88.
24. Wang H, An W, Cao R, et al., mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol Cell 2003; 12: 475-87.
25. Spyropoulou A, Gargalionis A, Dalagiorgou G, et al., Role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony formation. Neuromolecular Med 2014; 16: 70-82.
26. Rodriguez-Paredes M, Martinez de Paz A, Simõ-Riudalbas L, et al., Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene 2014; 22: 2807-13.
27. Esteller M,. Cancer epigenomics:DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-98.
28. Hauser D, Weber HP, Sigg HP,. Isolation and configuration of Chaetocin. Helv Chim Acta 1970; 53: 1061-73.
29. Greiner D, Bonaldi T, Eskeland R, et al., Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 2005; 1: 143-5.
30. Cherblanc FL, Chapman KL, Reid J, et al., On the histone lysine methyltransferase activity of fungal metabolite chaetocin. J Med Chem 2013; 56: 8616-25.
31. Tran HT, Kim HN, Lee IK, et al., Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A. J Korean Med Sci 2013; 28: 237-46.
32. Lakshmikuttyamma A, Scott SA, Decoteau JF, et al., Expression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene 2010; 29: 576-88.
33. Dong C, Wu Y, Wang Y, et al., Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene 2013; 32: 1351-62.
34. Lee YM, Lim JH, Yoon H, et al., Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia-inducible factor 1α pre-mRNA in mice and in vitro. Hepatology 2011; 53: 171-80.